Related Experiment Video

Updated: Aug 28, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.0K

Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors

Yanmeizhi Wu1, Shan Yu2, Hong Qiao1

  • 1Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Frontiers in Pharmacology
|September 19, 2022
PubMed

Insights

Immune checkpoint inhibitors (ICIs) leverage inflammatory factors to combat cancer. Understanding these factors and their role in immune-related adverse events (irAEs) is key to optimizing ICI therapy.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) activate the immune system against tumors.
  • Inflammatory factors are crucial in regulating programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) expression, key predictors of ICI response.
  • The tumor microenvironment (TME) components interact with immune factors, influencing ICI efficacy.

Purpose of the Study:

  • To review research on modulating inflammatory factors for enhanced anti-cancer responses using ICIs.
  • To explore the role of inflammatory factors in immune-related adverse events (irAEs) and their association with ICI efficacy.

Main Methods:

  • Literature review of current research on inflammatory factors and ICIs.
  • Analysis of the interplay between TME, immune cells, and inflammatory mediators.
  • Examination of the relationship between irAEs and inflammatory factor profiles.

Main Results:

  • Inflammatory factors significantly influence PD-L1 expression and ICI response.
  • IrAEs are linked to inflammatory factor-mediated positive feedback loops, potentially improving ICI outcomes.
  • Distinct inflammatory factor profiles are observed with different immune checkpoints and irAEs.

Conclusions:

  • Targeting inflammatory factors offers a strategy for optimizing anti-cancer responses with ICIs.
  • Further research into specific inflammatory factor roles can personalize ICI treatment and manage irAEs.
Keywords:
immune checkpoint inhibitorsimmune-related adverse eventsinflammatory factorsprogrammed death-1tumor microenvironment

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

640
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
5.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K